U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT07559942) titled 'Effect of Apiban Therapy on AVF Maturation in ESRD Patients' on April 24.
Brief Summary: End-stage renal disease (ESRD) is a growing global health burden, and the creation of a native arteriovenous fistula (AVF) is the gold standard for vascular access in patients requiring hemodialysis [1]. AVFs offer superior longevity, fewer infectious complications, and lower mortality rates compared to central venous catheters or synthetic grafts [2]. However, a significant limitation to their widespread success is the high rate of early failure, primarily due to failure to mature (FTM). FTM occurs in 20-40% of AVFs, rendering them unusable for d...